What is the dosage of ceftazidime for Pseudomonas pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftazidime Dosage for Pseudomonas Pneumonia

For Pseudomonas pneumonia, the recommended dosage of ceftazidime is 2 grams intravenously every 8 hours. 1, 2

Dosing Recommendations Based on Clinical Scenario

Standard Dosing

  • Ceftazidime 2 g IV every 8 hours is the standard dose for Pseudomonas pneumonia 1
  • This dosing is specifically indicated in the FDA label for lung infections caused by Pseudomonas species 1

Special Populations

  • Patients with normal renal function: 2 g IV every 8 hours 2
  • Patients with cystic fibrosis: May require higher doses (30-50 mg/kg IV) up to a maximum of 6 grams per day divided every 8 hours 1
  • Patients with renal impairment: Dose adjustment required based on creatinine clearance 1:
    • CrCl 50-31 mL/min: 1 g every 12 hours
    • CrCl 30-16 mL/min: 1 g every 24 hours
    • CrCl 15-6 mL/min: 500 mg every 24 hours
    • CrCl <5 mL/min: 500 mg every 48 hours

Administration Considerations

Method of Administration

  • Administer intravenously over 20-30 minutes 3
  • Continuous infusion may be considered as an alternative to intermittent bolus dosing in critically ill patients 4
  • Avoid intra-arterial administration 1

Duration of Therapy

  • Generally, ceftazidime should be continued for at least 2 days after signs and symptoms of infection have disappeared 1
  • For complicated infections, longer therapy may be required 1

Clinical Efficacy and Pharmacokinetics

  • Mean peak serum concentration after 2 g IV dose is approximately 58.5 μg/mL 3
  • Eight hours after dosing, mean plasma concentration is about 5 μg/mL 3
  • Mean plasma half-life is approximately 2.1-2.2 hours in patients with normal renal function 3

Important Clinical Considerations

Monitoring

  • Regular assessment of clinical response and bacterial cultures is recommended
  • In critically ill patients, monitoring of plasma drug concentrations may be beneficial as there can be significant variability in drug levels 4
  • Monitor renal function throughout treatment, especially in patients receiving other potentially nephrotoxic agents

Potential Pitfalls

  1. Inadequate dosing: Standard intermittent bolus dosing may result in inadequate plasma concentrations in some critically ill patients 4
  2. Development of resistance: Resistance can develop during therapy, particularly in patients with cystic fibrosis 5
  3. Renal toxicity: While ceftazidime is less nephrotoxic than aminoglycoside combinations, renal function should still be monitored 6

Combination Therapy Considerations

  • For patients with high risk of mortality or unstable hemodynamic status, combination therapy may be considered 2
  • Potential combinations include ceftazidime plus an aminoglycoside (gentamicin 5-7 mg/kg IV daily or amikacin 15-20 mg/kg IV daily) 2

Alternative Agents for Pseudomonas Pneumonia

If ceftazidime cannot be used, alternative options include:

  • Piperacillin/tazobactam 4.5 g IV every 6 hours 2
  • Cefepime 2 g IV every 8 hours 2
  • Meropenem 1 g IV every 8 hours 2
  • Imipenem 500 mg IV every 6 hours 2
  • Ciprofloxacin 400 mg IV every 8 hours 2

Remember that the choice of antibiotic should ultimately be guided by local susceptibility patterns and patient-specific factors, but ceftazidime 2 g IV every 8 hours remains the standard dosing for Pseudomonas pneumonia in patients with normal renal function.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.